BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Receives Equity Investment to Support Novel Immunotherapy Clinical Research
Proprietary targeted immunotherapy technology personalized to match unmet needs of advanced breast cancer patients Ongoing clinical studies of lead candidate, Bria-IMT, continue to show robust biological activity, excellent safety profile Breast cancer is one of the most commonly diagnosed cancers, with 2.1 million new cases expected in 2018 Global cancer immunotherapy market is projected to be valued at nearly $145 billion by 2022 An equity investment of C$500,000 into BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) by the company’s recently-appointed director, Jamieson Bondarenko (http://nnw.fm/jSjK6), underscores the vital importance of BriaCell’s proprietary drug development efforts to millions of cancer patients. BriaCell…